Abstract
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients.
Author supplied keywords
Cite
CITATION STYLE
Dagan, R., Hammitt, L. L., Nuñez, B. S., Cots, M. B., Bosheva, M., Madhi, S. A., … Villafana, T. (2024). Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season. Journal of the Pediatric Infectious Diseases Society, 13(2), 144–147. https://doi.org/10.1093/jpids/piad113
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
